Pentobarbital will reduce the level or outcome of linagliptin by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor. Use of other therapies is strongly recommended when linagliptin will be to be administered with a CYP3A4 inducer pentobarbital will decrease the extent or outcome of itraconazole by influencing hepatic/intestinal enzyme CYP3A4 metabolism. https://meisterx692ouw3.p2blogs.com/profile